Inhibition of human CYP3A4 by rationally designed ritonavir-like compounds: Impact and interplay of the side group functionalities

Eric R. Samuels and Irina F. Sevrioukova

SUPPORTING INFORMATION

Synthesis of CYP3A4 inhibitors, mass spectrometry and NMR data

¹H NMR spectra were recorded on Bruker DRX 400 MHz or DRX 500 MHz spectrometer. Chemical shifts (δ) are reported in ppm and J-values in hertz for the compound's solution in D₂O or deuterated chloroform (CDCl₃) with tetramethylsilane (TMS) as internal reference. All NMR data were processed using TopSpin 3.5 software. High resolution mass spectrometry data (HRMS) were obtained via ESI LC-TOF on a Waters (Micromass) LCT Premier spectrometer (Waters), with PEG as the calibrant. Thin layer chromatography (TLC) was performed using EMD Millipore silica gel 60 F₂₅₄ aluminum plates. Separation by column chromatography was performed using Fisher silica gel 60 (230-400 mesh). Where applicable, optical rotation was measured with a JASCO P-1010 polarimeter. All reactions were conducted with commercially available reagents (Aldrich, Thermo-Fisher, Alfa Aesar, Acros, Oakwood, Millipore). Anhydrous solvents were acquired through a solvent purification system (Inert PureSolv and JC Meyer systems) or purified according to standard procedures.

Synthesis of Analogs

General Procedure for Synthesis of Compounds **1a,b** Reference: Park, J. D., and Kim, D. H. (2002) J Med Chem **45**, 911-918

L-cysteine (10.0g, 82.5 mmol) was dissolved in methanol (MeOH; 150 ml). Sodium cyanoborohydride (5.18g, 82.5 mmol, 1 eq) was slowly added, followed by acetone (47.9g, 825 mmol, 10 eq), and the solution was stirred at room temperature overnight. On completion, the white precipitate was filtered, washed with MeOH, and dried to afford the pure product **1a** as a white powder (3.5g, 27%). ¹H NMR (400 MHz, D₂O) δ 3.98 (t, *J* = 4.5 Hz, 1H), 3.52 (quint, *J* = 6.6 Hz, 1H), 3.15 (dd, *J* = 4.8, 14.7 Hz, 1H) 3.04 (dd, *J* = 4.5, 14.8 Hz, 1H), 1.37 (d, *J* = 6.5 Hz, 6H). HRMS *m/z* calculated for C₆H₁₃NO₂S [M + Na]⁺: 186.0565. Found: 186.0569. The pure product **1b** was obtained as a white powder (3.55g, 22.5%). ¹H NMR (400 MHz, D₂O) δ 3.89 (t, *J* = 4.4 Hz, 1H), 3.63 (quint, *J* = 7.2 Hz, 1H), 3.12 (dd, *J* = 4.1, 14.9 Hz, 1H) 3.01 (dd, *J* = 4.6, 15.1 Hz, 1H), 2.08 (bs, 2H), 1.75-1.63 (bd, 6H). HRMS *m/z* calculated for C₈H₁₅NO₂S [M + H]⁺: 190.0902. Found: 190.0899.

Scheme 1: Synthesis of Cysteine Derivatives



Synthesis of Compound **2** References:

Park, J. D., and Kim, D. H. (2002) *J Med Chem* **45**, 911-918

Lee, G. H., Park, C. S., and Lee, H. W. (1988) Bull. Korean Chem. Soc. 9, 25-27

2-Bromoacrylic acid (1.1g, 7.3 mmol, 1.1 eq) was added to a solution of thioacetanilide (1.0g, 6.6 mmol) in dry toluene (20 ml). The mixture was stirred at 90°C for 1 h and then cooled to room temperature. The formed precipitate was filtered, washed with acetone, and recrystallized from MeOH:ethyl acetate (EtOAc):hexane (1:1:2) to afford the thiazolinium bromide intermediate. The intermediate was refluxed with 1.5 M HBr (30 ml) for 3 hours and then cooled to room temperature. The residue was concentrated under reduced pressure, dissolved in 48% HBr, and evaporated to obtain a crude, viscous material, which was recrystallized from 1-propanol:benzene (1:8) to obtain the racemic pure product (hydrobromide salt) **2** as a light tan solid (1.1g, 84.5%) ¹H NMR (400 MHz, D₂O) δ 7.54-7.26 (m, 5H), 4.43 (q, *J* = 4.5 Hz, 1H), 3.14 (dd, *J* = 3.6, 14.8 Hz, 1H) 2.90 (dd, *J* = 4.8, 14.8 Hz, 1H). HRMS *m/z* calculated for C₉H₁₁NO₂S [M + Na]⁺: 220.0408. Found: 220.0405. Optical rotation (in MeOH): 0.053±0.003.

Synthesis of Compound 3

N-tert-butyloxycarbonyl (*Boc*)-ethanolamine (2.0g, 12.4 mmol) was added to dry dichloromethane (DCM; 25 ml). To this solution, *p*-toluenesulfonyl chloride (3.55g, 18.6 mmol, 1.5 eq) and triethylamine (3.76g, 37.2 mmol, 3 eq) were slowly added at 0°C. The reaction was allowed to slowly come to room temperature overnight. When the reaction was completed,

DCM was evaporated and the crude mixture was purified using column chromatography (1:1 hexane:EtOAc), affording the pure product **3** as a viscous, opaque oil (3.46g, 88%) TLC: hexane/EtOAc 1:1 (Rf. 0.5). ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 8.4 Hz, 2H), 7.41 (d, *J* = 8.0 Hz, 2H), 4.83 (bs, 1H (NH)), 4.12 (t, *J* = 5.0 Hz, 2H), 3.43 (q, *J* = 5.1 Hz, 2H), 2.46 (s, 3H), 1.41 (s, 9H). HRMS *m/z* calculated for C₁₄H₂₁NO₅S [M + Na]⁺: 338.1038. Found: 338.1031.

General Procedure for Synthesis of Compounds 4a-c

To a DMF solution of compound **3** (0.5g, 1.6 mmol; 7 ml), compound **1a** (0.32g, 1.9 mmol, 1.23 eq) was added. To this mixture, 1 N NaOH (2 ml) was added, and the reaction was allowed to stir at 50°C overnight, where a white precipitate was formed. The precipitate was filtered, washed with ether, and dried, affording **4a** as a white crystalline powder (0.30g, 61%). HRMS m/z calculated for C₁₃H₂₆N₂O₄S [M + Na]⁺: 329.1511. Found: 329.1508. The product **4b** was obtained as a white powder (0.22g, 41%). HRMS m/z calculated for C₁₅H₂₈N₂O₄S [M + Na]⁺: 355.1667. Found: 355.1670. For **4c**, no precipitate formed. Therefore, the crude product was obtained by evaporating the solvent and was used in the next step without any further purification. HRMS m/z calculated for C₁₆H₂₄N₂O₄S [M + Na]⁺: 363.1354. Found: 363.1360



General Procedure for Synthesis of Compounds 5a-c

Compound 4a (0.2g, 0.65 mmol) was dissolved in DMF (5 ml). To this solution, 1-ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDAC; 0.19g, 0.98 mmol, 1.5 eq) and hydroxybenzotriazole (HOBt; 0.15g, 0.98 mmol, 1.5 eq) were added, followed by the addition of 3-(aminomethyl)pyridine (0.11g, 0.98 mmol, 1.5 eq) and N,N-diisopropylethylamine (DIPEA; 0.25g, 1.95 mmol, 3 eq). The reaction was stirred at room temperature overnight. Upon completion, the solvent was evaporated and the reaction mixture was diluted with ethyl acetate. The organic layer was then washed with saturated NaHCO₃, water, and brine. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the crude product, which was purified via column chromatography (95:5 EtOAc:MeOH). The pure product 5a was obtained as an opaque oil (0.091g, 35%). TLC: EtOAc/MeOH 90:10 (Rf. 0.32). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (m, 2H), 8.01 (t, J = 5.7 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 4.92 (bs, 1H) (NH)), 4.48 (d, J = 6.0 Hz, 2H), 3.33-3.30 (m, 3H), 3.04 (dd, J = 3.9, 13.4 Hz, 1H), 2.77 (m, 2H), 2.64 (t, J = 6.1 Hz, 2H), 1.45 (bs, 9H), 1.04 (dd, J = 6.2, 33.2 Hz, 6H). HRMS m/z calculated for $C_{19}H_{32}N_4O_3S [M + H]^+$: 397.2273. Found: 397.2289. The pure product **5b** was acquired as a clear oil (0.055g, 43%). TLC: EtOAc/MeOH 90:10 (Rf. 0.42). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (m, 2H), 7.97 (t, J = 6.5 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 4.92 (bs, 1H (NH)), 4.48 (d, J = 6.2 Hz, 2H), 3.32-3.29 (m, 3H), 3.04 (m, 1H), 2.77 (dd, J = 5.4, 8.0 Hz, 2H), 2.64 (t, J = 6.3 Hz, 2H) 1.71-1.53 (bm, 8H), 1.45 (bs, 9H). HRMS m/z calculated for $C_{21}H_{34}N_4O_3S$ [M + H]⁺: 423.2430. Found: 423.2426. The pure product 5c was obtained as a white fluffy solid (0.08g, 58%). TLC: EtOAc/MeOH 90:10 (Rf. 0.55). ¹H NMR (500 MHz, CDCl₃) δ 8.54 (m, 2H), 7.59 (d, J = 7.8 Hz, 1H), 7.46 (d, J = 5.6 Hz, 1H), 7.28-7.23 (m, 2H), 6.89 (t, J = 7.4 Hz, 1H), 6.71 (d, J = 8.2 Hz, 2H), 4.97 (bs, 1H (NH)), 4.66 (bs, 1H), 4.57 (dd, J = 6.3, 15.1 Hz, 1H), 4.46 (dd, J = 6.1, 15.1 Hz, 1H), 3.99 (bs, 1H (NH)), 3.35 (m, 2H), 3.22 (dd, J = 4.3, 13.6 Hz, 1H), 3.06 (q, J = 7.1 Hz, 1H), 2.67 (t, J = 6.3 Hz, 2H), 1.95 (bs, 1H (NH)), 1.48 (bs, 9H). HRMS m/z calculated for $C_{22}H_{30}N_4O_3S$ [M + Na]⁺: 453.1936. Found: 453.1947.

General Procedure for Synthesis of Compounds 6a,b

N-Boc-phenylalaninol (1.6g, 6.4 mmol) was added to dry DCM (15 ml). To this solution, *p*-toluenesulfonyl chloride (1.82g, 9.5 mmol, 1.5 eq) and triethylamine (1.93g, 19.1 mmol, 3 eq) were slowly added at 0°C. The reaction was allowed to slowly come to room temperature overnight. After the reaction completion, DCM was evaporated and the crude mixture was purified using column chromatography (1:1 hexane:EtOAc), affording the pure product **6a** as an off white powder (2.05g, 79%). TLC: hexane/EtOAc 1:1 (Rf. 0.64). ¹H NMR (500 MHz, CDCl₃) δ 7.84 (d, *J* = 8.0 Hz, 2H), 7.46-7.25 (m, 5H), 7.14 (d, *J* = 7.2 Hz, 2H), 4.78 (bs, 1H (NH)), 4.07 (t, *J* = 9.8 Hz, 2H), 3.95 (d, *J* = 7.8 Hz, 1H), 2.96 (m, 1H), 2.84 (m, 1H), 2.52 (s, 3H), 1.45 (s, 9H). HRMS *m/z* calculated for C₂₁H₂₇NO₅S [M + Na]⁺: 428.1508. Found: 428.1527. The pure product **6b** was acquired as off white crystals (1.76g, 72%). TLC: hexane/EtOAc 1:1 (Rf. 0.46). ¹H NMR (400 MHz, CDCl₃) δ 8.00 (bs, 1H (NH)), 7.76 (d, *J* = 8.1 Hz, 2H), 7.60 (t, *J* = 6.5 Hz, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 2H), 7.00 (s, 1H), 4.76 (bs, 1H (NH)), 4.20-4.12 (m, 1H), 4.00 (s, 2H), 3.02 (m, 2H), 2.45 (s, 3H), 1.41 (s, 9H). HRMS *m/z* calculated for C₂₃H₂₈N₂O₅S [M + Na]⁺: 467.1617. Found: 467.1633.

General Procedure for Synthesis of Compounds 7a-f

To a solution of compound **6a** (0.23g, 0.56 mmol) in DMF (5 ml), compound **1a** (0.11g, 0.68 mmol, 1.23 eq) was added. To this mixture, 1 N NaOH (2 ml) was added, and the reaction was allowed to stir at 50°C overnight. The crude product **7a** was obtained by evaporating the

solvent and used in the next step without any further purification. HRMS m/z calculated for $C_{20}H_{32}N_2O_4S$ [M + Na]⁺: 419.1981. Found: 419.1986. **7b** formed a white precipitate, which was collected, washed with H₂O, and dried (0.14g, 55%). HRMS m/z calculated for $C_{22}H_{34}N_2O_4S$ [M + Na]⁺: 445.2137. Found: 445.2130. **7c** HRMS m/z calculated for $C_{23}H_{30}N_2O_4S$ [M + H]⁺: 431.2004. Found: 431.1992. **7d** HRMS m/z calculated for $C_{22}H_{33}N_3O_4S$ [M + Na]⁺: 458.2090. Found: 458.2098. **7e** HRMS m/z calculated for $C_{24}H_{35}N_3O_4S$ [M + Na]⁺: 484.2246. Found: 484.2244. **7f** HRMS m/z calculated for $C_{25}H_{31}N_2O_4S$ [M + H]⁺: 470.2114. Found: 470.2111.





General Procedure for Synthesis of Compounds 8a-f

Crude 7a (0.3g, 0.75 mmol) was dissolved in DMF (5 ml). To this solution, EDAC (0.22g, 1.13 mmol, 1.5 eq) and HOBt (0.17g, 1.13 mmol, 1.5 eq) were added, followed by the addition of 3-(aminomethyl)pyridine (0.12g, 1.13 mmol, 1.5 eq) and DIPEA (0.29g, 2.25 mmol, 3 eq). The reaction was stirred at room temperature overnight. Upon completion, the solvent was evaporated and the reaction mixture was diluted with ethyl acetate. The organic layer was then washed with saturated NaHCO₃, water, and brine. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo* to give the crude product, which was purified via column chromatography (95:5 EtOAc:MeOH). The pure product 8a was obtained as yellow gum (0.054g, 20%). TLC: EtOAc/MeOH 90:10 (Rf. 0.48). ¹H NMR (400 MHz, CDCl₃) δ 8.53 (m, 2H), 7.98 (t, J = 5.5 Hz, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.33-7.19 (m, 5H), 4.66 (bs, 1H (NH)), 4.45 (d, J = 6.3 Hz, 2H), 3.99 (bs, 1H (NH)), 3.31 (q, J = 4.0 Hz, 1H), 3.04 (dd, J = 4.0, 13.4 Hz, 1H), 2.86 (d, J = 6.4 Hz, 2H), 2.81-2.72 (m, 2H), 2.64 (m, 2H), 1.40 (bs, 9H), 1.02 (dd, J = 6.2, 25.8 Hz, 6H). HRMS m/z calculated for C₂₆H₃₈N₄O₃S [M + H]⁺: 487.2743. Found: 487.2752. The pure product **8b** was acquired as an opaque oil (0.09g, 57%). TLC: EtOAc/MeOH 90:10 (Rf. 0.53). ¹H NMR (400 MHz, CDCl₃) δ 8.53 (m, 2H), 7.95 (t, J = 5.4 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.32-7.19 (m, 5H), 4.67 (bs, 1H (NH)), 4.45 (d, J = 6.2 Hz, 2H), 3.98 (bs, 1H (NH)), 3.30 (q, J = 3.8 Hz, 1H), 3.06 (m, 2H), 2.86

(d, J = 6.0 Hz, 2H), 2.78 (q, J = 7.2 Hz, 1H), 2.64 (m, 2H), 2.17 (bs, 2H), 1.81-1.50 (bs, 6H), 1.40 (bs, 9H). HRMS m/z calculated for C₂₈H₄₀N₄O₃S [M + H]⁺: 513.2899. Found: 513.2916. The pure product 8c was obtained as a white fluffy solid (0.03g, 19%). TLC: EtOAc/MeOH 90:10 (Rf. 0.62). ¹H NMR (500 MHz, CDCl₃) δ 8.54 (m, 2H), 7.59 (t, J = 4.0 Hz, 1H), 7.42 (m, 1H), 7.34-7.19 (m, 7H), 6.89 (m, 1H), 6.70 (q, J = 7.1 Hz, 2H), 4.77 (bd, J = 26.3 Hz, 1H). 4.67 (bs, 1H (NH)), 4.53 (td, J = 6.2, 15.7 Hz, 1H), 4.45 (td, J = 6.0, 15.7 Hz, 1H), 4.05 (bs, 1H (NH)), 3.97 (bs, 1H), 3.26-3.05 (m, 2H), 2.88 (m, 2H) 2.65 (m, 2H), 1.85 (bs, 1H (NH)), 1.46 (d, J = 9.7 Hz, 9H). HRMS m/z calculated for $C_{29}H_{36}N_4O_3S$ [M + Na]⁺: 543.2406. Found: 543.2408. The pure product **8d** was acquired as a white fluffy solid (0.07g, 30%). TLC: EtOAc/MeOH 90:10 (Rf. 0.42). ¹H NMR (500 MHz, CDCl₃) δ 8.58 (m, 2H), 8.44 (bs, 1H (NH)), 8.03 (t, J = 6.1 Hz, 1H), 7.68 (dd, J = 7.6, 24.2 Hz, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.32-7.23 (m, 1H), 7.17 (t, J = 7.1 Hz, 1H), 7.10 (s, 1H), 4.83 (bs, 1H (NH)), 4.47 (d, J = 5.7 Hz, 2H), 4.14 (bs, 1H (NH)), 3.36 (m, 1H), 3.10 (m, 2H), 2.84 (m, 1H), 2.78 (m, 1H), 2.69 (dd, J = 5.4, 16.2 Hz, 2H), 1.91 (bs, 2H), 1.46 (s, 9H), 1.05 (dd, J = 6.0, 26.3 Hz, 6H). HRMS m/z calculated for $C_{28}H_{39}N_5O_3S$ [M + Na]⁺: 548.2672. Found: 548.2670. The pure product **8e** was obtained as a white fluffy solid (0.09g, 36%). TLC: EtOAc/MeOH 90:10 (Rf. 0.5). ¹H NMR (500 MHz, CDCl₃) δ 8.64 (bs, 1H (NH)), 8.58 (m, 2H), 8.00 (t, J = 6.0 Hz, 1H), 7.67 (dd, J = 7.8, 21.5 Hz, 2H), 7.39 (d, J = 8.1 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.09 (s, 1H), 4.83 (bs, 1H (NH)), 4.47 (d, J = 6.2 Hz, 2H), 4.14 (bs, 1H (NH)), 3.34 (q, J = 4.0 Hz, 1H), 3.10-3.04 (m, 2H), 3.04 (m, 1H), 2.82 (q, J = 7.1 Hz, 1H), 2.78 (m, 1H), 2.71 (dd, J = 6.0, 13.1 Hz, 1H), 2.65 (dd, J = 5.4, 13.2 Hz, 1H), 2.08 (bs, 2H), 1.83-1.52, 1.31 (m, 8H), 1.47 (s, 9H). HRMS m/z calculated for $C_{30}H_{41}N_5O_3S$ [M + H]⁺: 552.3008. Found: 552.3007. The pure product **8f** was acquired as a white fluffy solid (0.032g, 17%). TLC: EtOAc/MeOH 90:10 (Rf. 0.6). ¹H NMR (500 MHz, CDCl₃) δ 8.53 (m, 2H), 8.37 (bs, 1H (NH)), 7.66 (d, J = 7.8 Hz, 1H), 7.56 (t, J = 6.9 Hz, 1H), 7.46-7.39 (m, 2H), 7.28-7.19 (m, 3H), 7.16 (q, J = 6.7 Hz, 1H), 7.03 (d, J= 5.5 Hz, 1H), 6.99 (m, 1H), 6.69 (dd, J = 7.8, 18.1 Hz, 2H), 4.82 (bs, 1H (NH)), 4.73 (bd, J = 35.8 Hz, 1H), 4.50 (td, J = 6.2, 15.3 Hz, 1H), 4.40 (dt, J = 5.0, 15.1 Hz, 1H), 4.17 (bs, 1H (NH)), 3.99 (bd, J = 54 Hz, 1H), 3.24-2.99 (m, 4H), 2.68 (m, 2H), 1.91 (bs, 1H (NH)), 1.48 (d, J = 15.4 Hz, 9H). HRMS m/z calculated for $C_{31}H_{37}N_5O_3S$ [M + Na]⁺: 582.2515. Found: 582.2527.

The purity of compounds **5a-c** and **8a-f** was >95% as determined by NMR, with the exception of occasional residual solvent (noted on spectra where applicable). HRMS and NMR spectra for all compounds are shown after Table S2.



Figure S1. Chemical structure and spectral changes induced by ritonavir in CYP3A4. Spectra of the ferric ligand-free and ritonavir-bound CYP3A4 are shown in black and red, respectively. Spectra of the ferrous and ferrous CO-bound forms are in green and blue, respectively. *Inset* is a titration plot and quadratic fit, which gives the K_s value of 17 nM.



Figure S2. *A*, Structural overlay of the ligand-free (PDB ID 5VCC; in gray) and **8c**-bound CYP3A4 (in shades of green). **8c** is in cpk representation. The F, F', G' and G helices are labeled to show that binding of **8c** leads to disorder of the F-F' loop, unwinding of the F-helix, and positional shift of the G-helix. No major alterations were observed in other ligand-bound structures (panel *B*): **5a** - cyan, **5b** - magenta, **5c** - yellow, **8a** - pale blue, **8b** - orange, **8c** - blue, **8d** - red, **8e** - black, and **8f** – green.

Table S1. Data collection and refinement statistics

Ligand	5a	5b	5c	8a	8b
PDB ID	6BCZ	6BD5	6BD6	6BD7	6BD8
Data statistics					
Space group	1222	1222	1222	1222	1222
Unit cell parameters	a = 77 Å, b = 101 Å,	a = 77 Å, b = 102 Å,	a = 77 Å, b = 101 Å,	a = 78 Å, b = 103 Å,	a = 76 Å, b = 101 Å,
	$c = 128$ Å; α, β, $\gamma = 90^{\circ}$	$c = 129$ Å; α, β, $\gamma = 90^{\circ}$	<i>c</i> = 127 Å; α, β, γ = 90°	<i>c</i> = 129 Å; α, β, γ = 90°	<i>c</i> = 124 Å; α, β, γ = 90
Molecules per					
asymmetric unit	1	1	1	1	1
Resolution range (Å)	79.39-2.23 (2.35-2.23) ^a	80.03-2.50 (2.64-2.50)	79.38-2.45 (2.58-2.45)	80.29-2.42 (2.55-2.42)	78.35-2.38 (2.51-2.38)
Total reflections	139,233	62,649	55,487	93,759	69,992
Unique reflections	24,881	17,153	17,706	19,640	18,695
Redundancy	5.6 (5.4)	3.7 (3.3)	3.1 (3.2)	4.8 (5.0)	3.7 (3.6)
Completeness	99.9 (99.9)	95.5 (93.4)	95.1 (97.7)	98.7 (99.2)	96.7 (95.5)
Average <i>I</i> / <i>σ</i> /	11.2 (0.9)	7.6 (0.2)	9.1 (0.5)	9.4 (0.6)	8.7 (0.4)
R _{merge}	0.049 (1.813)	0.057 (3.494)	0.049 (1.933)	0.056 (1.971)	0.052 (2.453)
R _{pim}	0.023 (0.858)	0.032 (2.125)	0.032 (1.270)	0.029 (0.951)	0.030 (1.408)
CC ½	0.999 (0.300)	0.997 (0.371)	0.997 (0.399)	0.998 (0.309)	0.994 (0.341)
Refinement statistics	S				
R/R _{free} ^b	20.0 (26.1)	20.9 (27.5)	20.4/26.7	19.3/26.4	21.2/26.9
Number of atoms:					
Protein	3815	3780	3693	3806	3753
Solvent	11	0	0	0	4
R.m.s. deviations:					
Bond lengths, Å	0.009	0.010	0.009	0.009	0.009
Bond angles, °	1.224	1.276	1.117	1.142	1.290

^aValues in brackets are for the highest resolution shell.

 ${}^{\rm b}{\it R}_{\rm free}$ was calculated from a subset of 5% of the data that were excluded during refinement.

Table S2. Data collection and refinement statistics

Ligand	8c	8d	8e	8f
PDB ID	6BDH	6BDI	6BDK	6BDM
Data statistics				
Space group	1222	1222	1222	1222
Unit cell parameters	<i>a</i> = 76 Å, <i>b</i> = 100 Å,	a = 78 Å, b = 102 Å,	a = 77 Å, b = 102 Å,	<i>a</i> = 77 Å, <i>b</i> = 101 Å,
	$c = 126$ Å; α, β, $\gamma = 90^{\circ}$	$c = 128$ Å; α, β, $\gamma = 90^{\circ}$	<i>c</i> = 128 Å; α, β, γ = 90°	<i>c</i> = 127 Å; α, β, γ = 90°
Molecules per				
asymmetric unit	1	1	1	1
Resolution range (Å)	78.25-2.25 (2.37-2.25) ª	79.92-2.57 (2.71-2.57)	79.90-2.67 (2.81-2.67)	79.33-2.60 (2.74-2.60)
Total reflections	89.557	77.790	53.812	70.890
Unique reflections	22,571	16,151	14,250	15,756
Redundancy	4.0 (4.0)	4.8 (4.8)	3.8 (3.5)	4.5 (4.6)
Completeness	97.5 (98.1)	97.8 (97.6)	96.9 (95.5)	99.9 (100.0)
Average I/ <i>o</i> /	7.6 (0.4)	9,4 (0.9)	8.0 (0.8)	7.6 (0.4)
R _{merge}	0.065 (2.814)	0.060 (1.817)	0.069 (1.522)	0.079 (3.396)
R _{pim}	0.035 (1.540)	0.030 (0.897)	0.039 (0.914)	0.042 (1.767)
CC ½	0.997 (0.488)	0.999 (0.315)	0.998 (0.355)	0.999 (0.303)
Refinement statistic	S			
R/R _{free} ^b	20.7 (28.0)	19.2 (24.5)	20.6/27.2	20.1/27.5
Number of atoms:				
Protein	3552	3785	3778	3712
Solvent	30	2	0	0
R.m.s. deviations:				
Bond lengths, Å	0.009	0.010	0.009	0.010
Bond angles, °	1.096	1.202	1.138	1.198

^aValues in brackets are for the highest resolution shell.

 ${}^{b}R_{free}$ was calculated from a subset of 5% of the data that were excluded during refinement.













































































